Despite concerns about safety and immunogenicity, German researchers have reported that efficacy is high and adverse reactions low with a two-component acellular pertussis vaccine used in preterm infants.
The researchers compared antibody responses and adverse reactions in 46 preterm infants and a control group of 50 term infants at Children's University Hospital in Frankfurt. The infants initially were vaccinated in the second month of life. A second dose was given within the next 8 weeks, and a third within the following 8 weeks. The two-component vaccine contained pertussis toxin (PT) and filamentous hemagglutinin (FHA).
Voelker R. Preemies and Pertussis Vaccine. JAMA. 1999;281(22):2078. doi:10.1001/jama.281.22.2078-JWM90004-2-1